Turning Point 2011
A selection of articles from the 2011 issue of Turning Point.
To see the entire publication, please download the PDF version. If you'd like to receive a print version of Turning Point in the mail, please complete this form.
How the Susan F. Smith Center for Women's Cancers is building on a legacy of successes.
Dana-Farber's experts answer questions about breast and ovarian cancer.
HER2, a growth factor receptor model, is active in a very small number of ovarian cancers, but its genetic cousin, HER3, has been estimated to be abnormal in 25 to 30 percent of ovarian tumors.
Researchers have begun probing the relatively unknown cellular territory of cervical cancer, hunting for new opportunities to block the mutated gene pathways driving the cancer.
The promise and potential limitations of a new class of cancer drugs.
Turning Point is published for supporters of Dana-Farber's Susan F. Smith Center for Women's Cancers. To learn more about the Susan F. Smith Center and its offerings, call Administrative Director Candace S. Lowe, ScD, at 617-632-2675.
Comments, suggestions, and requests to be added to or deleted from the mailing list may be sent to:
Dana-Farber Cancer Institute
Department of Communications
450 Brookline Ave.
Boston, MA 02115